Inspection Record

Galenova Inc. — Health Canada Inspection Findings

Health CanadaInspected 2021-05-10 7 findingsLabeling and packagingValidation and qualificationStability and storageOther quality systemDeviation, CAPA, and investigation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Labeling and packaging

The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).

2Validation and qualification

The qualification and/or verification of utilities and/or support systems was inadequate.

3Stability and storage

The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.

4Other quality system

The electronic system was not validated for its intended use.

5Other quality system

The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.

6Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

7Other quality system

The written specifications were inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2021-05-10. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Galenova Inc. findings history — including this company's other documents Health Canada documents, 2021 Go to Findings search